Phase 1 Clinical Trials for Healthy Volunteers
First-in-human drug safety and dosing studies that compensate healthy adults.
There are 449 actively recruiting Phase 1 clinical trials enrolling healthy volunteers. Phase 1 studies test investigational drugs for safety and dosing in small groups under close medical supervision. Updated daily from ClinicalTrials.gov.
What is a Phase 1 trial?
Phase 1 is the first stage of human testing. A small group of healthy volunteers receives the investigational drug to evaluate safety, tolerability, and pharmacokinetics. Participants are monitored closely — often as inpatients at a clinical pharmacology unit — and compensated for their time. These studies are reviewed and approved by an ethics committee before enrollment begins.
Showing 281–300 of 449 Phase 1 studies
A First-in-Human Single and Multiple Ascending Dose Study of MT-701
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
A Study of Elenestinib in Healthy Adult Female Participants
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
A Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Subjects in China
To Evaluate the Adhesion of TK-254RX on Healthy Participants
First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
Study of CM383 in Healthy Subjects
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants
A Phase I Study of HW201877 in Healthy Subjects
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes
Phase 1 FAQ
How much do Phase 1 trials pay?
Compensation varies by study duration and intensity. Inpatient Phase 1 studies (multi-day residential stays) typically pay $1,000–$5,000+. Outpatient studies with follow-up visits may pay $200–$1,500. Specific amounts are disclosed in the informed consent document.
Are Phase 1 trials safe?
Phase 1 trials carry some risk as participants receive an investigational drug. All studies are reviewed and approved by an ethics committee (IRB/HREC) before enrollment begins. Participants are monitored continuously and can withdraw at any time.
What happens during a Phase 1 study?
Typically you attend a screening visit, then either stay at the clinical unit (inpatient) or visit regularly (outpatient). Blood draws, vital signs, and other assessments are conducted at scheduled intervals. The study team monitors you throughout and provides meals and accommodation for inpatient stays.